The trial consisted of four parts (A–D), and based on the safety data obtained from part A, two global expansion cohorts—parts B and D—further examined the combination of osimertinib (80 mg once daily) plus savolitinib (300 mg or 600 mg once daily) in patients with EGFR-mutant, MET amplified/overexpressed NSCLC who had progressed on prior EGFR TKI therapy. The gene discussed is MET; the disease is non-small cell lung carcinoma.